BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30941997)

  • 1. Combination treatment for glioblastoma with temozolomide, DFMO and radiation.
    Alexiou GA; Vartholomatos E; I Tsamis K; Peponi E; Markopoulos G; A Papathanasopoulou V; Tasiou I; Ragos V; Tsekeris P; Kyritsis AP; Galani V
    J BUON; 2019; 24(1):397-404. PubMed ID: 30941997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells.
    Alexiou GA; Tsamis KI; Vartholomatos E; Peponi E; Tzima E; Tasiou I; Lykoudis E; Tsekeris P; Kyritsis AP
    J Neurooncol; 2015 Jun; 123(2):217-24. PubMed ID: 25935110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
    Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
    Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
    Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J
    BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
    Rubner Y; Muth C; Strnad A; Derer A; Sieber R; Buslei R; Frey B; Fietkau R; Gaipl US
    Radiat Oncol; 2014 Mar; 9(1):89. PubMed ID: 24678590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
    Castro-Gamero AM; Borges KS; Moreno DA; Suazo VK; Fujinami MM; de Paula Gomes Queiroz R; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
    Invest New Drugs; 2013 Aug; 31(4):858-70. PubMed ID: 23299390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
    Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
    Atif F; Patel NR; Yousuf S; Stein DG
    PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
    Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
    J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
    Brunetti A; Marinelli O; Morelli MB; Iannarelli R; Amantini C; Russotti D; Santoni G; Maggi F; Nabissi M
    Phytomedicine; 2019 Jan; 52():51-59. PubMed ID: 30599912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent.
    Haas B; Ciftcioglu J; Jermar S; Weickhardt S; Eckstein N; Kaina B
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):779-792. PubMed ID: 33315125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo.
    Liu T; Li A; Xu Y; Xin Y
    Cancer Med; 2019 Feb; 8(2):751-760. PubMed ID: 30656846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma.
    Rajesh Y; Biswas A; Kumar U; Banerjee I; Das S; Maji S; Das SK; Emdad L; Cavenee WK; Mandal M; Fisher PB
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12324-12331. PubMed ID: 32409605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.